EFG Asset Management (Americas)’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-155,452
Closed -$1.84M 136
2024
Q4
$1.84M Sell
155,452
-4,485
-3% -$53K 0.36% 88
2024
Q3
$1.85M Buy
159,937
+21,247
+15% +$242K 0.36% 84
2024
Q2
$1.47M Buy
138,690
+60,758
+78% +$666K 0.29% 91
2024
Q1
$821K Sell
77,932
-23,383
-23% -$252K 0.25% 98
2023
Q4
$1.14M Buy
101,315
+17,379
+21% +$169K 0.25% 99
2023
Q3
$980K Buy
+83,936
New +$949K 0.24% 96

Other funds holding ROIV

EFG Asset Management (Americas)'s ROIV Position: Q1 2025 in Review

EFG Asset Management (Americas) sold out of Roivant Sciences (ROIV) in Q1 2025, closing a stake of 155,452 shares — an estimated $1.84M sold.

EFG Asset Management (Americas) first reported a position in ROIV in Q3 2023 and held it in 6 quarters. The position peaked at $1.85M in Q3 2024. 312 funds tracked by Wall St. Rank hold ROIV as of Q1 2025.

  • EFG Asset Management (Americas) reported no remaining Roivant Sciences position as of Q1 2025 after selling out during the quarter.
  • EFG Asset Management (Americas) sold 155,452 Roivant Sciences shares in Q1 2025, an estimated $1.84M.
  • EFG Asset Management (Americas) first reported a position in Roivant Sciences in Q3 2023 and held it in 6 quarters.
  • EFG Asset Management (Americas)'s Roivant Sciences position peaked at $1.85M in Q3 2024.
  • 312 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2025.

Based on EFG Asset Management (Americas)'s 13F filing for Q1 2025, filed 8 May 2025.